Shots:
- The US FDA has granted IND clearance to LGNA-100, Laguna Biotherapeutics’ lead clinical candidate from the QUAIL platform, to initiate the P-I trial
- The P-I single ascending dose study will assess safety, tolerability, & mechanism of LGNA-100 via IV infusion in pediatric & young adults with high-risk acute leukemias & MDS post αβ-depleted HSCT
- LGNA-100 is a first-in-class attenuated live bacterial immunotherapy leveraging Listeria to expand γδ T cells for cancer killing & enhanced immunotherapy, with its QUAIL platform rationale to be presented at the ISCT’26
Ref: Globenewswire | Image: Laguna | Press Release
Related News: Immunome Reports the US FDA’s NDA Submission for Varegacestat to Treat Desmoid Tumors in Adults
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
